Loading...
XSHE
300519
Market cap377mUSD
Dec 05, Last price  
16.68CNY
1D
-3.70%
1Q
2.33%
Jan 2017
-58.81%
IPO
72.58%
Name

Zhejiang Xinguang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300519 chart
P/E
52.96
P/S
9.97
EPS
0.31
Div Yield, %
2.40%
Shrs. gr., 5y
Rev. gr., 5y
-1.68%
Revenues
268m
-1.01%
229,617,378249,854,530267,937,988292,109,437311,478,232315,313,658310,865,113276,257,365291,262,099283,080,271320,876,074351,488,810270,399,837267,659,927
Net income
50m
-21.70%
46,854,08956,837,67372,468,952105,651,545118,784,212118,958,793106,159,24687,995,76893,900,70698,976,352114,280,359108,821,01064,356,48050,389,992
CFO
53m
+0.27%
0057,511,46699,820,100124,840,438121,184,880124,232,04992,772,34798,266,202112,611,669142,355,309126,429,39753,290,42553,434,052
Dividend
May 29, 20240.4 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health foods. The company offers pharmaceutical products in the areas of cardiovascular and cerebrovascular diseases, and traumatic diseases, covering the aspects of respiratory system, digestive system, urinary system, pediatric diseases, and improving immunity. It also can produce 6 dosage forms with 49 approval numbers for drug production and 2 approval numbers for health food. It offers its products in the form of tablets, granules, syrups, powders, hard capsules, and oral solutions, as well as mixtures, including oral liquids. Zhejiang Xinguang Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Shengzhou, China.
URL
IPO date
Jun 24, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT